$449.74
-10.07-2.19%
Dern. MÀJ: Oct 16, 4:09 PM
$447.35
-12.46-2.71%
Madrigal Pharmaceuticals (MDGL) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-2.32 | $-4.04 | $-0.52 | $-1.99 |
| Actual | $-1.99 | $-3.25 | $-2.57 | $-5.08 |
| Surprise | +14.2% | +19.6% | -394.2% | -155.3% |
| Revenue | ||||
| Estimate | $349.6M | $301.0M | $313.0M | $247.2M |
| Actual | $364.3M | $311.3M | $321.1M | $287.3M |
| Surprise | +4.18% | +3.44% | +2.58% | +16.2% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-1.07 | $-0.45 | $-1.83 | $0.72 |
| Revenue | ||||
| Consensus | $405.0M | $445.9M | — | — |
| Trimestre Fiscal | Date de Déclaration | BPA Réel | BPA Estimé | Surprendre % |
|---|---|---|---|---|
| Q2 | Jul 30, 2026 | $-1.99 | $-2.32 | 14.2 % |
| Q1 | May 6, 2026 | $-3.25 | $-4.04 | 19.6 % |
| Q4 | Feb 19, 2026 | $-2.57 | $-0.52 | -394.2 % |
| Q3 | Nov 4, 2025 | $-5.08 | $-1.99 | -155.3 % |
| Trimestre Fiscal | Date de Déclaration | Revenu Réel | Revenu Estimé | Surprendre % |
|---|---|---|---|---|
| Q2 | Jul 30, 2026 | $364.25M | $349.63M | 4.18 % |
| Q1 | May 6, 2026 | $311.34M | $300.97M | 3.44 % |
| Q4 | Feb 19, 2026 | $321.08M | $313.00M | 2.58 % |
| Q3 | Nov 4, 2025 | $287.27M | $247.20M | 16.2 % |